In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Global Vision

Set Alert for Global Vision

European HTAs And Payers On How To Tackle The Evidence Problem

European payers and health technology appraisal organizations have warned that their decision making is being increasingly hampered by evidence gaps. Some solutions may lie in the better use of existing mechanisms, such as scientific advice and managed entry agreements, while others could be introduced through the overhaul of the EU pharmaceutical legislation.

Europe Approvals

From Chengdu To The World: Anticancer Takes Novel Approach To Cancer Drug Development

Inspired by the discovery of the phytochemical corynoline being a potential MYC synthetic lethality agent, Anticancer Bioscience has designed and identified preclinical candidates that could lead to first-in-class innovative drugs.

China Research & Development

‘One Nation, One Cluster’: The Unique Swiss Biotech Industry

Offering a challenging but blossoming free market model, strong academic institutions and an excellent track record in patents, the Swiss Biotech industry is one to watch. 

Business Strategies Switzerland

Pushing Forward: Venture Capitalist Priorities To Accelerate European Biotech

Sharing his thoughts on the European funding landscape, the importance of software, and sustainable investments, INKEF Capital’s Thijs Cohen Tervaert talks to In Vivo about his investment priorities.

Europe VC Playbook

The China Honeymoon Is Over: Global Medtech Must Think Decisively

China is transitioning to an economy driven by innovation and technology, with differential effects on foreign medtechs depending on their place in the value chain and type of innovation. China commentators have been updating the market.

China Market Access

Strategies To Encourage Universal Access To Gene Therapies

Inaccessible price points, development risk, and a lack of diversity in gene therapy R&D all feed into the imperfect state in which the industry's newest form of innovation exists. New approaches are needed if the patient populations that need these medicines the most can benefit.

Gene Therapy Market Access

Challenging Alzheimer's: Korean Firms Forge Ahead In Multiple Modalities

In Vivo takes an infographic look at where South Korea stands in the development of a wide-ranging set of drugs for Alzheimer’s disease and which companies are still in the challenging race.

South Korea Clinical Trials

The Regulatory Expert Targeting Sunnier Uplands For The Medtech Industry

The role and purpose of medical device regulation is now better understood than at any time in its history, and regulators are no longer seen as gatekeepers preventing business from happening. In Vivo Rising Leader 2022 Graeme Tunbridge, formerly at the MHRA and now a senior VP at BSI, is a champion of the climate of inclusivity.

Rising Leaders Medical Device

Israel’s Authority On Medical Robotics Lifts Curtain Behind Technion’s Success Stories

Moshe Shoham talks about the innovative technologies behind surgical robotics companies Microbot Medical, XACT Robotics, Tamar Robotics and ForSight Robotics, which were all spun out of his laboratory in Israel.

Robotic Surgery New Science

Bigger Money: Private Equity Grabs European VC

Deals show large investors’ appetite for early-stage biotech, but can VC and PE rub along?

Business Strategies Financing

Medtechs Track Changing Needs In Support Of Ukraine Healthcare

Ukraine’s medical supply needs have evolved since Russia launched its military invasion of the country on 24 February. EU healthcare decision makers and the medical technology industry have stood firm in their support of the besieged country, said MedTech Europe’s Jesús Rueda.

Ukraine Market Intelligence

How War In Ukraine Is Shifting Central Asia’s Pharma Map

Russia and Ukraine had been key players in the pharma markets of Central Asian and surrounding countries before the launch of the Russian invasion into its neighbor on 24 February. Because of this, both countries are poised to give ground in this growing regional market.

Supply Chain Market Access

Ukraine War Puts The Pharmaceutical Industry To The Test

Pharmaceutical leaders are responding to the many and varied challenges arising from the war in Ukraine.

Market Access Research & Development

Under Pressure: Are Enhanced Global Efforts Enough For Trial Transparency?

Increasing scrutiny is being placed on trial sponsors and regulators to improve trial data reporting. Researchers complain that, without access to specific data, results cannot be easily duplicated, which inhibits greater understanding of how medicines might work, adversely affecting treatment decisions and health care costs. Are penalties and public reprimands enough to change behavior?

Clinical Trials Policy

Europe’s Big Pharma Players Begin Tricky 2022 In Style

Big pharma players have embraced a tricky operating environment in 2022 so far, treading a tightrope with political and financial challenges impacting their decision making and threatening to blow them off balance. However, what is not in doubt is the healthy growth experienced by those companies based around mainland Europe and the UK.

Europe Growth

China Takes A Bigger Role In The World Pharma Stage

2021 saw a record number of novel drug launches and the size of the pipeline topped 20,000 candidates for the first time, new analysis shows, while China came of age as a pharma player.

Companies China
See All
UsernamePublicRestriction

Register